The years between 35 and 50 sit at a complex biological crossroads. The ovaries begin their long taper towards menopause, often quietly, before most women notice. At the same time the thyroid, the body’s central metabolic regulator, is undergoing changes that disproportionately affect women in this decade. The two systems do not behave independently, and yet conventional medicine continues to treat them as separate clinical questions, often with a single TSH measurement and a wait-and-see approach.
This review examines the evidence for what should be the new standard: paired testing of thyroid and reproductive hormones in women aged 35 to 50, with adrenal context where indicated. The case rests on three converging lines of research: the high prevalence of thyroid dysfunction in this age group, the overlapping symptom profile that makes symptom-based diagnosis unreliable, and the growing evidence that thyroid autoimmunity directly affects ovarian reserve.
How common is thyroid dysfunction in midlife women?
Thyroid dysfunction is one of the most common endocrinopathies in women, and its prevalence rises with age1. The two largest population studies provide a clear picture across iodine status. In a previously iodine-deficient region of northern Germany, between 8 and 10 % of women aged 40 to 59 had abnormally low TSH levels, rising to 14 to 20 % in those aged 60 to 7923. In an iodine-replete population, the Colorado Thyroid Disease Prevalence Study found elevated TSH consistent with hypothyroidism or subclinical hypothyroidism in approximately 10 % of women aged 45 to 54, rising to 21 % in those aged 75 and older4.
In other words, depending on where a woman lives and how her clinical biochemistry is interpreted, somewhere between 10 and 20 % of women in their 40s and 50s have measurable thyroid dysfunction, and a meaningful proportion of these cases are undiagnosed.
Autoimmune disease drives much of this. Anti-thyroid peroxidase (TPO) antibodies, the principal serological marker of Hashimoto’s thyroiditis, are found in around 7 % of teenage girls and rise progressively with age to roughly 30 % of women over 80. The reasons are multifactorial. Oestrogen modulates T-helper cell populations and influences thyroid peroxidase activity, and the immune fluctuations that accompany changing sex hormones during perimenopause appear to lower the threshold for autoimmune activation.
Why the symptoms are nearly identical
Hypothyroidism and perimenopause produce clinical pictures that are difficult to distinguish without specific testing. Both cause fatigue, weight gain (particularly central adiposity), brain fog, low mood, anxiety, sleep disturbance, hair thinning, and cold intolerance.
A 2020 study by Słopień and colleagues in the Journal of Endocrinological Investigation found that climacteric symptoms in euthyroid menopausal women correlate with thyroid hormone status even within the conventional reference range5. Where exactly a woman’s thyroid markers sit inside the so-called normal range appears to predict how severely she experiences menopausal symptoms, which has direct implications for how testing is interpreted.
Hyperthyroidism, often overlooked in midlife, also mimics perimenopause. Sweating, palpitations, sleep disorders, and nervousness occur in both. A large cross-sectional study by Boelaert and colleagues found that women over 61 with hyperthyroidism frequently present with few or no classical symptoms, making the diagnosis harder still6. The German review by Frank-Raue and Raue concludes that the threshold for measuring TSH in this age group should be deliberately low1.
Why TSH alone is not enough
The standard clinical approach to thyroid screening relies heavily on TSH alone, with a reference range typically spanning 0.3 to 4.0 mIU/L. Three problems make this insufficient for women aged 35 to 50.
First, TSH rises naturally with age in women. A French study of more than 156,000 TSH measurements (Rosario and colleagues) demonstrated that the upper limit of the TSH reference range increases continuously in women from age 30 onwards7. The American Thyroid Association has reported that the upper normal limit in 50-year-old women is approximately 4.0 mIU/L, rising by roughly 50 % by age 90. Using a single fixed cut-off across all ages misclassifies a substantial number of women in both directions.
Second, TSH normalises late in autoimmune thyroid disease. In the natural history of Hashimoto’s thyroiditis, antibodies appear first, followed by thyroid tissue infiltration, with TSH rising only once the gland’s reserve capacity is depleted. A woman can have positive anti-TPO antibodies and active thyroid autoimmunity for years while her TSH remains in range. The 2015 meta-analysis by Blum and colleagues in JAMA confirmed that subclinical thyroid dysfunction is itself an independent risk factor for adverse outcomes: subclinical hyperthyroidism increased vertebral fracture risk by approximately 3.6-fold8.
Third, TSH does not measure the active hormone reaching the cells. TSH reflects the brain’s instruction to the thyroid. Free T3 and free T4 reflect the active hormone available to tissues. Conversion of T4 to active T3 happens peripherally, is mediated by the deiodinase enzymes, depends on selenium and zinc, and is inhibited by elevated cortisol. A woman can have normal TSH and free T4 but low free T3 if conversion is impaired, often producing a clinical picture indistinguishable from overt hypothyroidism.
Thyroid autoimmunity is linked to ovarian decline
One of the more striking developments in the last three years is the body of evidence linking thyroid autoimmunity to diminished ovarian reserve, even in women with normal TSH.
The most recent and largest study, by Arlıer and Kükrer in Journal of Clinical Medicine (November 2025), evaluated 1,460 euthyroid infertile women aged 18 to 459. After adjustment for age, BMI, and TSH, anti-TPO positivity was associated with lower AMH and lower antral follicle count, with the strongest effect observed in women over 35. The authors concluded that thyroid autoimmunity may identify a subgroup of women at higher risk of accelerated reproductive ageing.
An earlier prospective study in International Journal of Molecular Sciences (Tańska and colleagues) compared 45 women with thyroid autoimmunity to 45 age-matched controls undergoing infertility treatment10. Anti-TPO-positive women had a median AMH of 1.7 ng/mL compared with 3.6 ng/mL in antibody-negative controls, and significantly lower antral follicle counts (medians of 8 versus 11). They also had a higher rate of sub-optimal response to ovarian stimulation, lower fertilisation rate, and fewer high-quality embryos.
A 2024 study in Frontiers in Endocrinology of 2,867 women undergoing first IVF cycles (Zhang and colleagues) found that both subclinical and overt hypothyroidism were independently associated with diminished ovarian reserve, suggesting that thyroid hormone insufficiency and thyroid autoimmunity contribute through separate but additive pathways11.
The clinical implication is significant. A woman in her late 30s presenting with subfertility, cycle changes, or early signs of perimenopause may be carrying undiagnosed autoimmune thyroid disease that is actively reducing her ovarian reserve, while her TSH reads as normal.
The HPO, HPT, and HPA axes are linked
The hypothalamic-pituitary-ovarian (HPO) axis, the hypothalamic-pituitary-thyroid (HPT) axis, and the hypothalamic-pituitary-adrenal (HPA) axis share signalling architecture and respond to each other. Three specific interactions matter for paired testing.
Oestrogen affects thyroid hormone bioavailability. A randomised crossover study by Shifren and colleagues found that oral oestrogen therapy raised thyroxine-binding globulin by approximately 40 %, reducing free thyroid hormone availability, while transdermal oestradiol had no such effect12. In a separate study, 10 of 25 women on levothyroxine required dose increases when oral hormone replacement was started13. This matters: a woman beginning oral menopausal hormone therapy needs her thyroid panel rechecked at two to three months. Transdermal delivery avoids this issue.
Cortisol suppresses T4 to T3 conversion. Elevated cortisol inhibits 5′-deiodinase, shunting T4 toward inactive reverse T3 instead of active free T3. Chronic stress can therefore produce a clinical picture of hypothyroidism with apparently normal TSH and total thyroid hormones. Diurnal salivary cortisol assessment or a DUTCH (dried urine) test can identify this pattern.
Thyroid dysfunction can accelerate reproductive decline. Hypothyroidism elevates prolactin, which suppresses GnRH and lowers oestrogen and testosterone production. The combination of autoimmune attack on the thyroid and prolactin-mediated suppression of the ovary may compound the natural reproductive decline of perimenopause.
What a paired-marker workup looks like
The 2024 EMAS Position Statement on Thyroid Disease and Menopause recommends a personalised, multi-system approach in this age group14. Translating that recommendation into specific markers, a comprehensive workup includes the following.
For the thyroid: TSH, free T4, free T3, reverse T3, anti-TPO antibodies, and anti-thyroglobulin antibodies. Conventional laboratory reference ranges typically place the upper limit of TSH at around 4.0 to 4.5 mIU/L. Functional medicine practice, drawn from observational data and clinical experience rather than randomised trials, typically targets TSH in the 0.3 to 2.0 mIU/L range, free T3 above approximately 3.2 pg/mL, and TPO antibodies below 9 IU/mL. The distinction between conventional and functional ranges is important: the conventional range identifies overt disease, while the functional range aims to identify subclinical dysfunction that may already be producing symptoms.
For the reproductive axis: oestradiol, progesterone, FSH, LH, total and free testosterone, and AMH. AMH is particularly useful in women aged 35 to 50 as a quantitative marker of ovarian reserve, though it does fluctuate. A single FSH measurement can be misleading in perimenopause because levels vary significantly cycle to cycle.
For adrenal context: diurnal salivary cortisol measured at four timepoints, or a DUTCH test, which provides cortisol metabolites in addition to free cortisol and can identify slow cortisol clearance, often itself a sign of underlying hypothyroidism.
What this means
The clinical case for paired testing in women aged 35 to 50 is no longer experimental. Three independent lines of evidence converge: thyroid dysfunction is common in this age group, its symptoms are clinically indistinguishable from perimenopause, and thyroid autoimmunity appears to accelerate ovarian reserve decline through mechanisms that may be independent of overt hormonal change.
For women, this means that a normal TSH does not rule out thyroid involvement, and that fatigue, weight gain, cycle changes, and mood symptoms in midlife deserve a more complete laboratory workup than a single-marker approach can provide. For clinicians, it means that treating perimenopause and thyroid dysfunction as separate problems, sequentially investigated, can delay diagnosis by years.
The next frontier in research is whether early identification and treatment of subclinical or autoimmune thyroid disease in women aged 35 to 50 modifies the trajectory of perimenopausal symptoms or preserves ovarian reserve. Trials addressing this question directly are limited, but the observational and mechanistic data already support a more thorough diagnostic approach now, while the trials catch up.